341 related articles for article (PubMed ID: 34663326)
1. Effects of BNT162b2 mRNA vaccine on COVID-19 infection and hospitalisation amongst older people: matched case control study for England.
Mason TFD; Whitston M; Hodgson J; Watkinson RE; Lau YS; Abdulrazeg O; Sutton M
BMC Med; 2021 Oct; 19(1):275. PubMed ID: 34663326
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study.
Lopez Bernal J; Andrews N; Gower C; Robertson C; Stowe J; Tessier E; Simmons R; Cottrell S; Roberts R; O'Doherty M; Brown K; Cameron C; Stockton D; McMenamin J; Ramsay M
BMJ; 2021 May; 373():n1088. PubMed ID: 33985964
[TBL] [Abstract][Full Text] [Related]
3. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data.
Haas EJ; Angulo FJ; McLaughlin JM; Anis E; Singer SR; Khan F; Brooks N; Smaja M; Mircus G; Pan K; Southern J; Swerdlow DL; Jodar L; Levy Y; Alroy-Preis S
Lancet; 2021 May; 397(10287):1819-1829. PubMed ID: 33964222
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of BNT162b2 and ChAdOx1 nCoV-19 COVID-19 vaccination at preventing hospitalisations in people aged at least 80 years: a test-negative, case-control study.
Hyams C; Marlow R; Maseko Z; King J; Ward L; Fox K; Heath R; Tuner A; Friedrich Z; Morrison L; Ruffino G; Antico R; Adegbite D; Szasz-Benczur Z; Garcia Gonzalez M; Oliver J; Danon L; Finn A
Lancet Infect Dis; 2021 Nov; 21(11):1539-1548. PubMed ID: 34174190
[TBL] [Abstract][Full Text] [Related]
5. Infections, hospitalisations, and deaths averted via a nationwide vaccination campaign using the Pfizer-BioNTech BNT162b2 mRNA COVID-19 vaccine in Israel: a retrospective surveillance study.
Haas EJ; McLaughlin JM; Khan F; Angulo FJ; Anis E; Lipsitch M; Singer SR; Mircus G; Brooks N; Smaja M; Pan K; Southern J; Swerdlow DL; Jodar L; Levy Y; Alroy-Preis S
Lancet Infect Dis; 2022 Mar; 22(3):357-366. PubMed ID: 34562375
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of BNT162b2 and mRNA-1273 covid-19 vaccines against symptomatic SARS-CoV-2 infection and severe covid-19 outcomes in Ontario, Canada: test negative design study.
Chung H; He S; Nasreen S; Sundaram ME; Buchan SA; Wilson SE; Chen B; Calzavara A; Fell DB; Austin PC; Wilson K; Schwartz KL; Brown KA; Gubbay JB; Basta NE; Mahmud SM; Righolt CH; Svenson LW; MacDonald SE; Janjua NZ; Tadrous M; Kwong JC;
BMJ; 2021 Aug; 374():n1943. PubMed ID: 34417165
[TBL] [Abstract][Full Text] [Related]
7. Assessment of Effectiveness of 1 Dose of BNT162b2 Vaccine for SARS-CoV-2 Infection 13 to 24 Days After Immunization.
Chodick G; Tene L; Patalon T; Gazit S; Ben Tov A; Cohen D; Muhsen K
JAMA Netw Open; 2021 Jun; 4(6):e2115985. PubMed ID: 34097044
[TBL] [Abstract][Full Text] [Related]
8. Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study.
Maneikis K; Šablauskas K; Ringelevičiūtė U; Vaitekėnaitė V; Čekauskienė R; Kryžauskaitė L; Naumovas D; Banys V; Pečeliūnas V; Beinortas T; Griškevičius L
Lancet Haematol; 2021 Aug; 8(8):e583-e592. PubMed ID: 34224668
[TBL] [Abstract][Full Text] [Related]
9. Is the BNT162b2 COVID-19 vaccine effective in elderly populations? Results from population data from Bavaria, Germany.
Gomes D; Beyerlein A; Katz K; Hoelscher G; Nennstiel U; Liebl B; Überla K; von Kries R
PLoS One; 2021; 16(11):e0259370. PubMed ID: 34739520
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness of COVID-19 vaccines in older adults in Colombia: a retrospective, population-based study of the ESPERANZA cohort.
Arregocés-Castillo L; Fernández-Niño J; Rojas-Botero M; Palacios-Clavijo A; Galvis-Pedraza M; Rincón-Medrano L; Pinto-Álvarez M; Ruiz-Gómez F; Trejo-Valdivia B
Lancet Healthy Longev; 2022 Apr; 3(4):e242-e252. PubMed ID: 35340743
[TBL] [Abstract][Full Text] [Related]
11. Association of BNT162b2 mRNA and mRNA-1273 Vaccines With COVID-19 Infection and Hospitalization Among Patients With Cirrhosis.
John BV; Deng Y; Scheinberg A; Mahmud N; Taddei TH; Kaplan D; Labrada M; Baracco G; Dahman B
JAMA Intern Med; 2021 Oct; 181(10):1306-1314. PubMed ID: 34254978
[TBL] [Abstract][Full Text] [Related]
12. Impact of a delayed second dose of mRNA vaccine (BNT162b2) and inactivated SARS-CoV-2 vaccine (CoronaVac) on risks of all-cause mortality, emergency department visit, and unscheduled hospitalization.
Wong CKH; Xiong X; Lau KTK; Chui CSL; Lai FTT; Li X; Chan EWY; Wan EYF; Au ICH; Cowling BJ; Lee CK; Wong ICK
BMC Med; 2022 Mar; 20(1):119. PubMed ID: 35296305
[TBL] [Abstract][Full Text] [Related]
13. Safety Monitoring after the BNT162b2 COVID-19 Vaccine among Adults Aged 75 Years or Older.
Choi YY; Kim MK; Kwon HC; Kim GH
J Korean Med Sci; 2021 Nov; 36(45):e318. PubMed ID: 34811980
[TBL] [Abstract][Full Text] [Related]
14. Estimated Effectiveness of Coadministration of the BNT162b2 BA.4/5 COVID-19 Vaccine With Influenza Vaccine.
McGrath LJ; Malhotra D; Miles AC; Welch VL; Di Fusco M; Surinach A; Barthel A; Alfred T; Jodar L; McLaughlin JM
JAMA Netw Open; 2023 Nov; 6(11):e2342151. PubMed ID: 37938846
[TBL] [Abstract][Full Text] [Related]
15. Introduction of the BNT162b2 vaccine during a COVID-19 nursing home outbreak.
McEllistrem MC; Clancy CJ; Buehrle DJ; Lucas A; Pruskowski J; Handler SM; Decker BK
Am J Infect Control; 2021 Oct; 49(10):1237-1241. PubMed ID: 34363871
[TBL] [Abstract][Full Text] [Related]
16. Receipt of COVID-19 and seasonal influenza vaccines in California (USA) during the 2021-2022 influenza season.
Andrejko KL; Myers JF; Openshaw J; Fukui N; Li S; Watt JP; Murray EL; Hoover C; Lewnard JA; Jain S; Pry JM;
Vaccine; 2023 Feb; 41(6):1190-1197. PubMed ID: 36585281
[TBL] [Abstract][Full Text] [Related]
17. BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers.
Lustig Y; Sapir E; Regev-Yochay G; Cohen C; Fluss R; Olmer L; Indenbaum V; Mandelboim M; Doolman R; Amit S; Mendelson E; Ziv A; Huppert A; Rubin C; Freedman L; Kreiss Y
Lancet Respir Med; 2021 Sep; 9(9):999-1009. PubMed ID: 34224675
[TBL] [Abstract][Full Text] [Related]
18. Comparative Effectiveness of BNT162b2 and mRNA-1273 Vaccines in U.S. Veterans.
Dickerman BA; Gerlovin H; Madenci AL; Kurgansky KE; Ferolito BR; Figueroa Muñiz MJ; Gagnon DR; Gaziano JM; Cho K; Casas JP; Hernán MA
N Engl J Med; 2022 Jan; 386(2):105-115. PubMed ID: 34942066
[TBL] [Abstract][Full Text] [Related]
19. Safety and tolerability of the novel 2019 coronavirus disease (COVID-19) vaccines among people with epilepsy (PwE): A cross-sectional study.
Massoud F; Ahmad SF; Hassan AM; Alexander KJ; Al-Hashel J; Arabi M
Seizure; 2021 Nov; 92():2-9. PubMed ID: 34391030
[TBL] [Abstract][Full Text] [Related]
20. The initial impact of a national BNT162b2 mRNA COVID-19 vaccine rollout.
Zaqout A; Daghfal J; Alaqad I; Hussein SAN; Aldushain A; Almaslamani MA; Abukhattab M; Omrani AS
Int J Infect Dis; 2021 Jul; 108():116-118. PubMed ID: 33992763
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
